Free shipping on all orders over $ 500

Elotuzumab

Cat. No. M22514
Elotuzumab Structure
Synonym:

BMS 901608; PDL 063; HuLuc 63

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Elotuzumab is a First-in-Class monoclonal antibody directed against the SLAMF7 receptor, it specifically binds to signaling lymphocyte activating molecule family member 7 (SLAMF7) and activates the body's immune response to attack and kill multiple myeloma cells. Elotuzumab exerts its anti-myeloma effects mainly through ADCC and activation of NK cells. Elotuzumab results in improved response and outcome when combined with other antimyeloma agents. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM).

Chemical Information
CAS Number 915296-00-3
Solubility (25°C) PBS
Storage Store at -80°C
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] No authors listed. Aust Prescr. Elotuzumab for multiple myeloma

[2] No authors listed. Elotuzumab

[3] Meletios A Dimopoulos, et al. N Engl J Med. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

[4] No authors listed. Elotuzumab

[5] Sagar Lonial, et al. N Engl J Med. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Related Products
M3554 (anti-GD2 ADC)

M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody. M3554 has anti-tumor activity.

OGT2115

OGT2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT2115 has anti-angiogenic properties (IC50 = 1 μM).

DiosMetin 7-O-β-D-Glucuronide

DiosMetin 7-O-β-D-Glucuronide is an antioxidant constituent in the fruits of Luffa cylindrical.

Bendazac L-Lysine

Bendazac L-Lysine is an aldose reductase (AR) inhibitor, which can be used to inhibit the activity of AR in the eye to prevent cataracts.

Ro5-3335

Ro5-3335 acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation.

  Catalog
Abmole Inhibitor Catalog




Keywords: Elotuzumab, BMS 901608; PDL 063; HuLuc 63 supplier, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.